fbpx
Loading Events

AI Antibody Drug Discovery – the BigHat story with founders Mark DePristo and Peyton Greenside

Mark DePristo, CEO

Mark is a leader in applying computational and statistical techniques to biomedical challenges in genomics and biochemistry. Before BigHat, he founded the Genomics team in Google Brain, was VP of Informatics at SynapDx, and was Co-Director of Medical and Population Genetics at the Broad Institute. He has a BA in CS and Math from Northwestern, a PhD in Biochemistry from Cambridge as a Marshall Scholar, and was a Damon Runyon Cancer Research Fellow at Harvard. Dr. DePristo’s academic articles are widely published with more than 72,000 citations.

Peyton Greenside, CSO

A pioneer of deep learning applied to life science problems, Peyton has developed computational, statistical, and AI/ML techniques to model, understand, and optimize biological sequences in academia and industry. Peyton was an inaugural Schmidt Science Fellow, a computational biologist at the Broad Institute, a scientific founder of Valis, and holds a PhD from Stanford University (Accel Innovation Scholar), an MPhil in Computational Biology from Cambridge University (Herchel Smith Scholar), and a BA in Applied Math from Harvard.

Lunch Served

Click to Join Zoom Webinar
Go to Top